Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Operating Expenses (2016 - 2025)

Coherus Oncology's Operating Expenses history spans 13 years, with the latest figure at $58.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 234.04% year-over-year to $58.6 million; the TTM value through Dec 2025 reached $223.3 million, down 1.21%, while the annual FY2025 figure was $223.3 million, 1.21% down from the prior year.
  • Operating Expenses for Q4 2025 was $58.6 million at Coherus Oncology, up from $55.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $250.4 million in Q1 2021 and bottomed at $17.6 million in Q4 2024.
  • The 5-year median for Operating Expenses is $98.5 million (2022), against an average of $98.4 million.
  • The largest annual shift saw Operating Expenses plummeted 89.06% in 2024 before it surged 234.04% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $112.9 million in 2021, then decreased by 14.23% to $96.8 million in 2022, then surged by 65.66% to $160.4 million in 2023, then tumbled by 89.06% to $17.6 million in 2024, then soared by 234.04% to $58.6 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Operating Expenses are $58.6 million (Q4 2025), $55.9 million (Q3 2025), and $55.7 million (Q2 2025).